

# THE REWARDS AND CHALLENGES OF CONSTRUCTING PATIENT REGISTRIES IN MEXICO: LEARNED LESSONS FROM THREE NATIONAL REGISTRIES

Alejandra Medina-Rivera  
Laboratorio Internacional de Investigación sobre el Genoma Humano  
Universidad Nacional Autónoma de México

Simons Institute, Computational Challenges in Very Large-Scale 'Omics'  
July 2022




## PATIENT REGISTRIES

- Patient registries are organized systems that collect, store and analyze information about individuals living with a particular disease or condition.
- They are useful for clinical research, setting of clinical trials and improvement of patient care, and when clinical data is complemented with genomic information, they provide further opportunities for research



## Diversity in Genetic and Genomic studies



- LATAM shows great diversity due to constant migration and differences in ecosystems that led to adaptation leaving marks in Native American genomes.
- These factors have shaped populations with diverse genetic backgrounds in which genetic variation manifests in unique effects on complex traits, including the immune system.

# Electronic records in Mexico

- 73.5% of Mexico inhabitants are affiliated with either public or private health services
  - 51% are affiliated with the Instituto Mexicano del Seguro Social (IMSS)
  - 35.5% Instituto de Salud para el Bienestar (INSABI)
- 33 million people in the country remain with no health services insurance
  - 48.49% have no effective access to health services.
- NOM-024-SSA3-2012, issued in 2012, regulates the Electronic Health Record Information Systems and sets the mechanisms to record, exchange and consolidate information.
- The diversity of electronic clinical records and database storage systems greatly hinder data sharing and interaction among health institutions.




# Major genomic resources in Mexico

- **Mexico City Prospective Study**

- Survey in two regions within Mexico City
  - Coyoacan (Middle – Upper class)
  - Iztapalapa (Low –Middle class)
- Medical survey with anthropometric measurements
- Exome sequencing for 150,000 people
- Recontact based on address.
- 10,000 participants were recontacted between 2015-2019
- Focus on diabetes, cardiovascular diseases and smoking outcomes
- Major publication 2022
- Lead by Oxford University and UNAM

- **MexBiobank**

- Based on samples from the National Health Survey 2000
  - Generated genotyped data for 6,000 individual across the country.
  - 40,000 samples
  - General health survey
  - No recontact
  - Autoimmune diseases were not included
  - Mental health surveys were not included
  - Preprint published 2022
  - Lead by LANGEBIO, Irapuato, Mexico
- 

# Challenges

- Recontact participants for further stages of research
- Decentralization of data acquisition, most patient studies are centered in Mexico City in the National Institutes of Health.
- Collaboration engagement with the medical community.
- Lack of trust towards the scientific community (INEGI survey on Perception on science and technology, 2017).


## DEEPLY PHENOTYPED REGISTRIES

- Comprehensive medical history survey
- Ethics and consent contemplate the option to be recontacted for follow-up surveys or analysis.
- Ethics are approved for biobanking
- Mental health, cognitive assessments and lifestyle surveys are included
- Nation wide recruitment perspective.
- Public engagement through continuous communication with participants









# MEXICAN TWIN REGISTRY

- Surveys selected to match the Australian and United Kingdom Twins Registries to enable comparative analysis.
- Focus on mental health and cognitive development.
- CONACYT funding to biobank swap samples from 250 twin pairs. Including functional magnetic resonance.
  - 100 pairs have been bio-banked

twinsMX  
REGISTRO MEXICANO DE GEMELOS




Conmemorando  
la **semana** del  
**cerebro**,  
aquí te platicamos  
sobre si **se hereda**  
la conectividad cerebral

twinsMX  
REGISTRO MEXICANO DE GEMELOS


twinsmxofficial.unam.mx

**Total by July 2022**


**n = 3205**  
1158 (579 pairs)  
2047 (single)




**Distribution by sex**



**Distribution by zygoty**



**Distribution by Age**



# Coherence Rate and Heritability of Myopia and Astigmatism



Talía V. Román-López

		Twin 1	
		Yes	No
Twin 2	Yes	<b>Concordant</b>	<b>Discordant</b>
	No	<b>Discordant</b>	

C

C + D

n = 1399 families	Probandwise Concordance	
	Mz	Dz
<b>Myopia</b>	<b>0.74</b>	<b>0.50*</b>
<b>Astigmatism</b>	<b>0.74</b>	<b>0.54*</b>

\*  $p < 0.05$ . Tested by Likelihood ratio test

Heritability# in Mexican Population		
<b>Myopia</b>	<b>62%</b>	
<b>Astigmatism</b>	<b>67%</b>	

#Estimated by ACE Bivariate Cholesky Modeling



Ciencia de Frontera, 2019  
No. 6390



Sarael Alcauter  
PhD  
INB, UNAM



Alejandra Ruiz-Contreras  
PhD  
FP, UNAM




Alejandra Medina-Rivera  
PhD  
LIIGH, UNAM




Miguel Rentería  
PhD  
QIMR



Talía V. Román-López



Diego Ramírez



Brisa García Vilchis




Sofía Pradel



Oscar Aldana




Itzamná Sánchez



Vanessa Murillo



Diego Zenteno



Zaida Espinosa



Xóchitl Díaz



Ian Espinosa



Regina Casa Madrid



Andrea Tapia



# MEXICAN NETWORK FOR PARKINSON'S RESEARCH

---

- Launched in 2021
- Patient enrollment through certified Neurologists
- The shortage of Neurologists with valid certification along with their workload in the public sectors, restricts the massive extension of the registry.
- 192 registries have been recorded.
- Surveys designed to allow for cross data analysis between the Australian Parkinson's Genetics Study and the Latin American Research Consortium on the Genetics of Parkinson's Disease.
- MJFF funding to genotype 2500 patients and 2500 controls
- APDA financing allows for deep phenotyping of cognitive decay and mental health surveys of 500 patients and 500 controls.



# Recruitment



- 13 clinical sites in 8 regions + 2 registry sites for controls (RegGenoLab y Laboratorio de Neurogenómica Cognitiva UNAM-CU)
- 8 assistants for interview sessions online or through phone calls

Region	Start	Neurologist
B California	2021-12	Damaris Vazquez
CDMX	2022-10	Karla Salinas
CDMX	2021-12	Nadia Gandarilla
CDMX	2022-03	Sara Millán
Guanajuato	2021-11	Maritza Valadez
Jalisco	2022-01	Omar Cárdenas
Jalisco	2022-03	Teresa Pérez
Jalisco	2022-05	Moisés Rubio
Michoacán	2021-10	Eugenia Morelos
Querétaro	2021-11	Lucero Ugalde
Querétaro	2022-03	Yamil Matuk
San Luis Potosí	2022-05	Ildelfonso Rodríguez
Sinaloa	2021-10	Diana Deras

# Recruitment: Public Engagement


- 13 neurologists actively registering patients in RedCap in 8 regions
- Sampling days calendarized throughout the year in selected sites
- Public engagement sessions (FB-live, Miércoles de ConCiencia UAQ, Club Hacienda)
- Open campaigning for controls recruitment




¿Quieres ayudarnos a entender las causas genéticas y ambientales de la **Enfermedad de Parkinson** en nuestra población? **Participa con nosotros, ¡te estamos buscando!**

**Participa como control**  
**Requisitos**

- Tener 45 años cumplidos o más
- Ser mexicano (o haber residido la mayor parte de tu vida en México)
- Saber leer y escribir
- Donar una muestra de ADN por hisopado bucal
- No tener familiares consanguíneos de algún paciente con Enfermedad de Parkinson
- No tener diagnóstico de alguna enfermedad neurodegenerativa

**¿Dónde?**  
UNAM Campus Juriquilla, Querétaro  
UNAM Facultad de Psicología, CDMX  
Contáctanos a través de  RedMEXPD



ABRIL. MES DE CONCIENCIACIÓN SOBRE EL PARKINSON 

Sábado 9 de abril  
10 a.m.

*Charla online*  
**NO ES SOLO TEMBLOR**  
¿Qué otros síntomas puedo tener si tengo enfermedad de Parkinson?



Dra. Eugenia Morelos

 LIVE



**Terapia ocupacional**  
en la enfermedad de Parkinson



M. Lorena Palafox Ramirez  
Terapeuta ocupacional

**Jueves 26 de mayo, 19:00 h**

Por Facebook Live

 **Red Mexicana de Investigación en Parkinson**

UNIVERSIDAD AUTÓNOMA DE QUERÉTARO  
FACULTAD DE CIENCIAS NATURALES

**“MIÉRCOLES CONCIENCIA UAQ”**  
Miércoles  
17:00 hrs  
Aula 5

**CHARLAS DE CULTURA CIENTÍFICA**



La Universidad Autónoma de Querétaro, a través de su Facultad de Ciencias Naturales en colaboración con el CECEQ “Manuel Gómez Morín”, presenta en ABRIL.

ENTRADA LIBRE

16 “LA SOCIEDAD IMPULSANDO LA INVESTIGACIÓN EN SALUD A NIVEL MUNDIAL”  
Con la participación de las investigadoras de la UNAM:  
Dra. Alejandra Mejías Rivera, Laboratorio Internacional de Investigación sobre el Genoma Humano, UNAM.  
Dra. Alejandra Ruiz Contreras, Laboratorio de Neurogenética Cognitiva, Coordinación de Psicología y Neurociencias, Facultad de Psicología, UNAM.  
Dra. Soraya Alcazar Solísman, Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM.

20 “¿QUÉ SON LOS REGISTROS POBLACIONALES Y CUÁL ES SU UTILIDAD EN LA INVESTIGACIÓN EN EPIDEMIOLOGÍA GENÉTICA?”  
Con la participación de las investigadoras de la UNAM:  
Dra. Cécilia Gómez Jiménez, Laboratorio Internacional de Investigación sobre el Genoma Humano, UNAM.  
Dra. Tala Román López, Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM.  
Dra. Ana Brita García Viana, Laboratorio de Neurogenética Cognitiva, Coordinación de Psicología y Neurociencias, Facultad de Psicología, UNAM.

27 “HECHO EN MÉXICO: ¿QUÉ NOS ENSEÑAN LOS REGISTROS POBLACIONALES SOBRE LAS ENFERMEDADES COMPLEJAS?”  
Con la participación de Paula Reyes-Pérez y Ana Laura Hernández-Ledezma, Estudiantes de Doctorado del Laboratorio Internacional de Investigación sobre el Genoma Humano, UNAM.

 Miércoles ConCiencia UAQ  CECEQro

SECRETARÍA DE EDUCACIÓN  
CECEQ  
CENEA  
CENEG  
CENEP  
CENES  
CENEX  
CENFY  
CENIZ  
CENJ  
CENL  
CENM  
CENP  
CENS  
CENW  
CENX  
CENY  
CENZ

Av. Constituyentes 5, 1<sup>er</sup> piso, San Pedro, Cda. Villas del Sur, Querétaro, Qro.  
www.ceceq.com.mx



# Clinical and epidemiological characterization of anxiety and depression patterns in Parkinson's patients in Mexico



13 active registry sites in clinics in 8 states + 2 control registry sites



DNA extraction and processing

164 samples sent to Cleveland for genotyping

98 patients and 66 controls



Paula Reyes



## Records per instrument

	Clinical basic data	SCL-90R	PAS	STAI	ST-DEP
<b>Cases</b>	142	27	27	25	23
<b>Controls</b>	129	17	46	45	38
<b>Total</b>	271	44	73	70	61

## Per sex

## Age at recruitment

	Male	Female	Min	Max	Mean (SD)
<b>Cases</b>	86 (56.20%)	67 (43.79%)	43	88	58.11 (9.37)
<b>Controls</b>	36 (27.69%)	94 (72.30%)	42	91	68.38 (9.41)





# Acknowledgements

## INB

- **Sarael Alcauter Solórzano**
- Ian Espinosa
- Aranza Piña

## Neurogenomics Lab

- **Alejandra Ruiz Contreras**
- Alejandra Lázaro
- Ulises Caballero
- Talía Román

## QMIR Berghofer

- Dr. Miguel Rentería

## LARGE-PD

- Dr. Ignacio Mata
- Miguel Inca

## LIIGH:

- Jair García
- Luis Aguilar
- Alejandra Castillo



## RegGenoLAB:

- Paula Reyes
- Victor Flores
- Ana Hernández
- Karen Nuñez
- Juan Villarreal
- Oscar Aldana
- Diego Buoker
- Xóchitl Díaz
- Sofía Salazar

## Mexican neurologists

- Damaris Vazquez
- Karla Salinas
- Nadia Gandarilla
- Sara Millán
- Maritza Valadez
- Omar Cárdenas
- Teresa Pérez



**Patients, care partners and unaffected controls**



- Leonardo Arteaga
- Mónica Padilla
- Ingrid Salazar
- María José Fernández
- Alfonso Bravo
- Itzel Ortiz
- Diego Duarte

## Hospital Ángeles Team

- Patricia Ledesma
- Eduardo Gastellum
- Julissa Ugalde
- Gabriela Hernández

## GP2 team

- Sara Bandres
- Alastair Noyce
- Sumit Dey

## NGOs

- Laura Olmos (Parkinson Laredo).
- Alejandro Galindo y Margarita Vallejo (Asociación Mexicana de Parkinson, A.C.)


## Social media

- Erika Rentería
- Mauricio Guzmán



## Lupus

- ⌘ Systemic Lupus Erythematosus (SLE) is a multi-systemic autoimmune disease with a widely heterogeneous set of clinical manifestations
- ⌘ Previous studies have shown the influence of ethnicity and socioeconomic status on SLE's risk and prognosis.
- ⌘ Earlier and more severe development of SLE, as well as a higher rate of mortality, has been observed in Latin American, North American Mestizos, African descendants and Native American patients



# Lupus prevalence in Mexico



- ⦿ No epidemiological surveillance in place
- ⦿ Affects mostly women (9:1) and people between the ages of 20 and 40 years old.
- ⦿ Prevalence 20/100,000.
- ⦿ Incidence between 1.8 and 7.6 cases/100,000-año.

Regions	Year of study	cases / 100,000 hab
Chih, NL, Sin, Yuc y CDMX	2005	70
Nuevo León	2008-2009	40
Yucatán	2011	70
Oaxaca	2016	90



- ⦿ Launched in May 2021
- ⦿ Initial recruitment through social media based on self reported status and self assessment of clinical manifestations
- ⦿ Close collaboration with patient communities
- ⦿ 5 rheumatologists joined in the last year to recruit patients



**LUPUS** RGMX  
Registro Mexicano de Lupus

## Progress

May 2021-May 2022




726



94.2%  
684

5.8%  
42

36 ( $\pm 10$ ) años  
Range 18-79 años  
Mostly between  
29 and 44 años



48.9%  
355





27 ( $\pm 10$ ) years



Antimalaria drugs 54.9%  
Glucocorticoids 46.2%




IMSS 43.4%  
Private 30.6%  
ISSSTE 10.6%





# LUPUS<sub>RGMX</sub>

Registro Mexicano de Lupus



Número de participantes


- 1-10
- 11-25
- 26-50
- 76-100
- 151-175



LIIGH-UNAM  
INTERNATIONAL LABORATORY FOR  
HUMAN GENOME RESEARCH



## Socio economical status





- 8,900-15,600 MXN per month
- 35-54% destined to food.
- Communication, transport, education and health


E	\$5,400
D	\$8,900
D+	\$12,300
C	\$15,600
C	\$19,900




# Comorbidities and clinical manifestations



# Quality of life



# Allele specific expression patterns in systemic lupus erythematosus during tolerogenic induction



Why?



Tolerogenic dendritic cells are an immunotherapy alternative for autoimmune disease

Progress:

- Lupus patients: 15
- Controls: 6



# Allele specific expression in Systemic Lupus Erythematosus on immune tolerance induction.



# Acknowledgements

## Research collaborators

Dra. Claudine Liliane Irles Machuca (INPer).  
Dra. Florencia Rosetti Sciutto (INCMNSZ).  
Dra. Selene Fernández (LANGEBIO).  
Dr. Gabriel Frontana Vázquez (HGR1-IMSS).  
Dra. Gosia Trynka (Sanger).  
Dra. María Gutiérrez-Arcelus (Brigham and Women's Hospital).  
Dra. Alejandra Ruíz (Fac. Psicología, UNAM).  
Dra. Deshiré Alpizar Rodríguez  
Dra. Estefania Torres-Valdez (IMSS)  
Dr. Sarael Alcauter (INB)  
Dra. Talía Román (INB)

## Patient communities

Dra. Donají Domínguez (Fundación Proayuda Lupus Morelos).  
Sandy Vera (LupusMX)

## REGGENOLAB

Ana Hernandez-Ledesma  
Juan Ernesto Villarreal  
Ale Zayas  
Victor Flores  
Paula Reyes  
Eli Fajardo  
Karen Nuñez Reza  
Oscar Aldana  
Leo Arteaga  
Mónica Padilla

## Social media

Mauricio Guzmán Araiza  
Andrea

## Rheumatologists

Dra. Deshiré Alpizar Rodríguez.  
Dra. Estefania Torres-Valdez.  
Dr. Guillermo Gamez.  
Dra. Angélica Peña.  
Dra. Talía Díaz.



**LUPUS**<sup>RGMX</sup>  
Registro Mexicano de Lupus



**CONACYT**

Ciencia de Frontera, 2019  
No. 11311

# Pediatric Lupus



Dra. Talía Díaz Prieto  
Pediatric rheumatologist  
Hospital San José Tec  
Salud





Dra. Claudia Gonzaga-Jauregui  
Assistant Professor  
LIIGH- UNAM






# Mapping immune cell diversity across Latin America





# Mapping immune cell diversity across Latin America



## Aim 2 Regulatory Networks

Integration of Regulatory Networks




Transcriptome profile



scATAC-seq

Population specific regulatory interactions



Regulatory effects of genetic variation

TF

nnATTGCACAATnn

~~nnATTGTACAATnn~~

nnATTGTACAATnn

## Aim 3 PBMC Biobank







**Alejandra Medina-Rivera**  
UNIVERSIDAD  
NACIONAL  
AUTÓNOMA DE  
MÉXICO



**Gosia Trynka**  
WELLCOME SANGER  
INSTITUTE  
UNITED KINGDOM



**Yesid Cuesta Astroz**  
COLOMBIAN INSTITUTE OF  
TROPICAL MEDICINE, CES  
UNIVERSITY  
COLOMBIA



**Benilton de Sá Carvalho**  
UNIVERSITY OF CAMPINAS  
- UNICAMP  
BRAZIL



**Marcela Katherine  
Sjöberg Herrera**  
PONTIFICIA  
UNIVERSIDAD  
CATÓLICA DE CHILE  
CHILE



**Pablo Alberto Romagnoli**  
INSTITUTO UNIVERSITARIO  
DE CIENCIAS BIOMÉDICAS  
DE CÓRDOBA  
ARGENTINA



**Luis Alberto Tataje  
Lavanda**  
ESCUELA PROFESIONAL  
DE MEDICINA  
HUMANA,  
UNIVERSIDAD PRIVADA  
SAN JUAN BAUTISTA  
PERU



**Maximiliano Berro  
Castiglioni**  
HOSPITAL DE CLÍNICAS,  
UNIVERSITY OF THE  
REPUBLIC  
URUGUAY

## Summary

- Launching patient registries in Mexico is a challenge but is also rewarding.
- Public engagement is key for the success of these projects.
- These resources can have great impact on research in the country and potentialize functional genomic studies in the Mexican population.
- Infrastructure can be used to help establish other registries.
- Produced data will help increase diversity in genomic samples.
- Challenge: How to access consortia data?
  - Data access for LARGE-PD is centralized in Terra.
  - LATAM institutions do not have established processes to pay for these type of services
  - The advantage of centralized repositories for integrative analysis will go to countries and institutions that can pay for the service (Google cloud).

THANKS!

---

# Progress by survey



LARGE-PD						MEX-PD								
LARGE PD minimal set						Metal health				Cognitive function				
Datos mínimos para envío de muestra														
Parte I	Parte II	Parte III	Genealogía	Consentimiento informado	MoCA	UPDRS	UPDRS	SCL-90R	PAS	IDARE	IDER	Reserva cognitiva	CBS	
Datos de identificación clínica del probando, incluyendo sede y neurólogo que realiza el registro, criterios de inclusión y exclusión.	Datos del probando incluyendo edad, ancestría, síntomas motores y no motores, uso de levodopa y agonistas dopaminérgicos,.	Datos acerca de exposiciones ambientales del participante: antecedentes de residencia, fuentes de agua, consumo de sustancias; traumatismos, antecedentes laborales, exposición a pesticidas y metales pesados, uso de medicamentos.	Árbol genealógico simple de 3 generaciones donde se incluyen enfermedades conocidas en la historia familiar	Firma del documento de Consentimiento Informado	Montreal (traducción al español del Montreal Cognitive Assessment), Evalúa los siguientes dominios cognitivos: atención y concentración; funciones ejecutivas, memoria, lenguaje, habilidades visuoespaciales, razonamiento conceptual, cálculo y orientación	UPDRS-neuros, Sección del MDS-UPDRS (Official MDS Spanish Translation, 2015), correspondiente a Parte II: Aspectos Motores de las Experiencias de la Vida Diaria (M-EVD).	UPDRS-asistentes, Sección del MDS-UPDRS (Official MDS Spanish Translation, 2015), correspondiente a Parte I: Aspectos No-Motores de las Experiencias de la Vida Diaria (nM-EVD).	Inventario de Síntomas-Revisado, de Derogatis, evalúa el grado de malestar psicológico actual que experimenta una persona, en 9 dimensiones: Somatización, Obsesiones, Sensitividad Interpersonal, Depresión, Ansiedad, Hostilidad, Ansiedad Fóbica, Ideación Paranoide y Psicoticismo.	Escala de Ansiedad de Parkinson. Escala calificada por un observador o paciente de 12 ítems con tres subescalas, para la ansiedad persistente y episódica, y el comportamiento de evitación.(Parkinson Anxiety Scale, traducida al español)	Inventario de Ansiedad Rasgo-Estado (IDARE), adaptado al español, empleado para medir dos dimensiones básicas de la ansiedad: como rasgo y como estado, con 20 ítems para cada dimensión.	Inventario de Depresión Rasgo-Estado (IDERE o IDER), adaptado al español, empleado para medir dos dimensiones de la depresión: como rasgo y como estado, con 20 ítems para cada dimensión	Cognitive Reserve Index questionnaire (CRIQ; versión en español), que estima la reserva cognitiva de un individuo a través de la recopilación de información sobre toda su vida adulta.	Conjunto de 8 tareas neurocognitivas para evaluar los siguientes dominios: Memoria, Razonamiento, Habilidad verbal y Concentración	
<b>Casos</b>	<b>158</b>	<b>142</b>	<b>82</b>	<b>37</b>	<b>79</b>	<b>91</b>	<b>113</b>	<b>23</b>	<b>27</b>	<b>27</b>	<b>25</b>	<b>23</b>	<b>Por iniciar</b>	<b>3</b>
<b>Control es</b>	<b>136</b>	<b>129</b>	<b>107</b>	<b>82</b>	<b>47</b>	<b>33</b>	<b>2</b>	<b>2</b>	<b>17</b>	<b>46</b>	<b>45</b>	<b>38</b>	<b>Por iniciar</b>	<b>0</b>
<b>Totales</b>	<b>294</b>	<b>271</b>	<b>189</b>	<b>119</b>	<b>126</b>	<b>124</b>	<b>115</b>	<b>25</b>	<b>44</b>	<b>73</b>	<b>70</b>	<b>61</b>	<b>0</b>	<b>3</b>

# THE STAR OF THE SHOW

When you want a more elegant approach, the dynamic presence of PANTONE Very Peri shines as the star of the show in this palette of classics and neutrals whose understated stylishness conveys a message of timeless sophistication.



# AMUSEMENTS



Use this color palette when you want to tell a joyous and whimsical story. In this palette, PANTONE Very Peri injects a sense of playful freshness into the design, exuding a good-natured warmth that quickly engages the eye.